VBI Vaccines Inc (OTCPK:VBIVQ)

$ 0.0005 -0.0003 (-37.5%) Market Cap: 14,000.00 Enterprise Value: 38.14 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

VBI Vaccines Inc Hepatitis B Portfolio Discussion Transcript
Feb 28, 2023
VBI Vaccines Inc at H C Wainwright Hepatitis B Virus (HBV) Virtual Conference Transcript
Oct 18, 2022
VBI Vaccines Inc to Discuss on FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults - Corporate Call Transcript
Dec 01, 2021
VBI Vaccines Inc at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript
Oct 05, 2021
VBI Vaccines Inc To Discuss Preclinical Data, Phase 1b Study Design, and VBI's COVID-19 And Betacoronavirus Development Strategy Call Transcript
Sep 29, 2021
VBI Vaccines Inc Phase 1/2 Trial of VBI-2902a Data Update Call Transcript
Jun 29, 2021
VBI Vaccines Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 23, 2021
VBI Vaccines Inc at National Securities Biotech Investor Summit (Virtual) Transcript
Apr 28, 2021
VBI Vaccines Inc. - Special Call Transcript
Dec 08, 2020
VBI Vaccines Inc. - Special Call Transcript
Nov 18, 2020
VBI Vaccines Inc. - Special Call Transcript
Oct 20, 2020
VBI Vaccines Inc. - Special Call Transcript
Aug 26, 2020
VBI Vaccines Inc. - Special Call Transcript
Jan 09, 2020
VBI Vaccines Inc Reviewing top-line data from PROTECT Transcript
Jun 17, 2019
VBI Vaccines Inc. - Special Call Transcript
Apr 25, 2019

VBI Vaccines Inc. - Special Call Transcript

Nov 18, 2020 / 01:30PM GMT

Release Date Price: $83.1 (-3.82%)

Transcript

Jeffrey R. Baxter

VBI Vaccines Inc. - President, CEO & Director

Good morning, and thank you all for joining us on the call today. I'm Jeff Baxter, CEO of VBI, and I'm very excited to share with you this initial positive and encouraging interim Phase Ib/IIa data from VBI-2601, our immunotherapeutic candidate for the treatment of chronic hepatitis B infection.

This study has been conducted by our partner, Brii Biosciences, at clinical sites in New Zealand, Australia, Thailand, South Korea, Hong Kong and China.

A brief word on Brii. In these unprecedented pandemic times, Brii has been an exemplary partner who have executed flawlessly this study against an incredibly difficult backdrop. I would like to recognize our achievement and express our thanks.

This is the first interim readout from this study, and these early data from the low dose cohorts are very encouraging, providing us with a human proof-of-concept that leads us to believe the VBI-2601, BRII-179 could be an effective and critical component of a functional cure for chronic hepatitis B. Here with me to discuss the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.